Back to Search
Start Over
CalliSpheres® drug-eluting beads (DEB) transarterial chemoembolization (TACE) is equally efficient and safe in liver cancer patients with different times of previous conventional TACE treatments: a result from CTILC study.
- Source :
-
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico [Clin Transl Oncol] 2019 Feb; Vol. 21 (2), pp. 167-177. Date of Electronic Publication: 2018 Jul 12. - Publication Year :
- 2019
-
Abstract
- Purpose: To assess the efficacy and safety of drug-eluting beads transarterial chemoembolization (DEB-TACE) in liver cancer patients with different times of previous conventional transarterial chemoembolization (cTACE) treatments.<br />Methods: 367 liver cancer patients about to receive DEB-TACE treatment were enrolled in this prospective cohort study. All patients were divided into no previous cTACE group (NPC group), 1-2 times previous cTACE group (PC group) and triple or above previous cTACE group (TPC group) according to the times of previous cTACE treatments.<br />Results: There was no difference in complete response (CR) (P = 0.671) and objective response rate (ORR) (P = 0.062) among three groups. Additionally, no difference in overall survival (OS) among groups (P = 0.899) was found. As to liver function, most liver function indexes were deteriorative at 1 week after DEB-TACE operation, but returned to baseline at 1-3 months after DEB-TACE operation in all three groups, while percentage of abnormal total bile acid (TBA) patients was higher in TPC group than NPC and PC groups at 1-3 month post-DEB-TACE (P = 0.018). As for safety profiles, the incidence of pain during DEB-TACE operation was lower in TPC group compared to NPC and PC groups (P = 0.005), while no difference of other adverse events was found during and 1 month post-DEB-TACE treatment among three groups.<br />Conclusion: DEB-TACE treatment was equally efficient and tolerated in liver cancer patients with different times of previous cTACE treatments.
- Subjects :
- Adult
Aged
Chemoembolization, Therapeutic mortality
Drug Carriers
Female
Humans
Kaplan-Meier Estimate
Liver Neoplasms mortality
Male
Microspheres
Middle Aged
Neoplasm Recurrence, Local mortality
Neoplasm Recurrence, Local therapy
Treatment Outcome
Antibiotics, Antineoplastic administration & dosage
Chemoembolization, Therapeutic methods
Doxorubicin administration & dosage
Liver Neoplasms therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1699-3055
- Volume :
- 21
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
- Publication Type :
- Academic Journal
- Accession number :
- 30003530
- Full Text :
- https://doi.org/10.1007/s12094-018-1902-8